Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Non-Current Deferred Tax Liability (2017 - 2018)

Soleno Therapeutics (SLNO) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $1.6 million as the latest value for Q4 2018.

  • Quarterly Non-Current Deferred Tax Liability changed 0.0% to $1.6 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2018, changed 0.0% year-over-year, with the annual reading at $1.6 million for FY2018, 0.0% changed from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2018 was $1.6 million at Soleno Therapeutics, roughly flat from $1.6 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $1.6 million in Q4 2017, with the low at $1.6 million in Q4 2017.